Blue Ash Therapeutics raises $2M-plus to push drug over finish line
Blue Ash Therapeutics has raised more than $2 million to help push its first and only drug across the regulatory finish line with a pivotal clinical trial. Started more than a year ago by pharmaceutical industry veterans Greg Flexter and Kevin Malloy, the Cincinnati company is finishing development of Azimilide, a drug that can work […]